Pharmacokinetic (PK) and Pharmacodynamic (PD) assays are the engine room for Lead Optimisation Drug Discovery.
With our years of experience in delivering programmes into preclinical development, we understand the need for robust, pharmacologically sensitive, high-throughput, multi-modal in vivo endpoints that can be put into context with drug exposure levels.
We can offer almost any dosing route and preclinical species that you might require.
We have experts in early stage compound formulation to ensure maximal systemic/CNS exposure.
We deploy a myriad of in vivo and ex-vivo endpoints that we use to critique potential small molecule, protein and antibody therapeutics for their PK/PD relationship. These include:-
- Behaviour/In vivo:-
Transgenic animals (rats and mice) to model specific mechanistic targets
Standard locomotor activityTemperature (rectal anmicrochipped)
24/7 Circadian Rhythm
Laser Doppler cutaneous blood flow
Pharmaco EEG (see a link [here])
Seizure models(see a link [here])
Laboras complex behavioural assessment (see a link [here])
Systemic drug exposure
CNS /peripheral target organ tissue drug exposure
Cerebrospinal Fluid (CSF) drug exposure
Biomarker assessment (RNA and Protein; Please consult us)
Blood glucose assessment